Trastuzumab Deruxtecan Prolongs PFS in Pretreated HR+, HER2-Low and -Ultralow Metastatic Breast Cancer
Zanidatamab Shows Durable Responses With Longer Follow-up in Pretreated HER2+ Biliary Tract Cancer
Cabazitaxel/Abiraterone Combination Prolongs PFS vs Abiraterone in mCRPC
Pembrolizumab Plus Sacituzumab Govitecan Shows Nonsignificant Trend Toward Improved PFS in HR+ Breast Cancer